- JP-listed companies
- KNC Laboratories Co., Ltd.
- Balance sheet
KNC Laboratories Co., Ltd. (6568) Balance sheet
Market cap
¥9.6B
P/E ratio
12.4x
Develops and manufactures specialized organic chemicals for pharmaceutical, electronics, and biotech companies to accelerate their product development.
| 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Cash and cash equivalents | - | 1,263 | 5,413 | 3,072 | 1,476 | 1,963 | 1,974 | 2,297 | 3,312 | 2,386 | 2,173 |
| Total current assets | - | 3,185 | 7,247 | 4,775 | 4,335 | 5,137 | 6,347 | 7,459 | 8,559 | 7,475 | 7,811 |
| Property, plant and equipment, net | - | 5,340 | 5,135 | 6,628 | 7,696 | 6,961 | 6,909 | 7,200 | 8,475 | 11,147 | 12,277 |
| Marketable securities, non-current | - | 135 | 189 | 265 | 314 | 265 | 238 | 221 | 344 | 233 | 333 |
| Total non-current assets | - | 5,654 | 5,522 | 7,228 | 8,435 | 7,644 | 7,604 | 7,945 | 10,063 | 12,677 | 13,833 |
| Total assets | - | 8,839 | 12,769 | 12,002 | 12,771 | 12,781 | 13,952 | 15,405 | 18,622 | 20,152 | 21,644 |
| Short-term debt | - | 300 | - | - | - | - | 200 | 500 | - | - | - |
| Long-term debt, current | - | 680 | 1,279 | 778 | 460 | 360 | 440 | 440 | 658 | 852 | 1,103 |
| Total current liabilities | - | 2,295 | 2,974 | 2,333 | 1,716 | 1,287 | 2,047 | 2,728 | 2,969 | 2,269 | 2,726 |
| Total non-current liabilities | - | 2,360 | 1,059 | 215 | 1,228 | 1,373 | 1,330 | 931 | 2,566 | 4,364 | 4,837 |
| Total liabilities | - | 4,655 | 4,032 | 2,547 | 2,944 | 2,660 | 3,377 | 3,659 | 5,535 | 6,632 | 7,564 |
| Retained earnings | - | 4,033 | 4,844 | 5,587 | 5,913 | 6,119 | 6,568 | 7,830 | 9,069 | 9,567 | 10,078 |
| Stockholders' equity | 3,783 | 4,184 | 8,737 | 9,455 | 9,827 | 10,121 | 10,575 | 11,745 | 13,087 | 13,520 | 14,081 |